<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702648</url>
  </required_header>
  <id_info>
    <org_study_id>AC-082-101</org_study_id>
    <nct_id>NCT02702648</nct_id>
  </id_info>
  <brief_title>First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders</brief_title>
  <official_title>Single-center, Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this first-in-man study is to investigate whether a new drug for
      neurological disorders is safe and well-tolerated when administered orally to healthy adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1, 2016</start_date>
  <completion_date type="Actual">March 6, 2017</completion_date>
  <primary_completion_date type="Actual">March 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to end of study (up to Day 11)</time_frame>
    <description>Treatment-emergent adverse events and treatment-emergent serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Up to end of study (up to Day 11)</time_frame>
    <description>Vital signs include diastolic and systolic blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in ECG variables</measure>
    <time_frame>Up to end of study (up to day 11)</time_frame>
    <description>ECG variables are to be recorded at rest using a standard 12-lead ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) following single ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to 96 hours post dose</time_frame>
    <description>Cmax is derived from the observed plasma concentration-time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) following single ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to 96 hours post dose</time_frame>
    <description>tmax is derived from the observed plasma concentration-time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)] following single ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to 96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) following single ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to 96 hours post dose</time_frame>
    <description>AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification [AUC(0-t)] and from zero to infinity [AUC(0-inf)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) following multiple ascending doses</measure>
    <time_frame>Up to 96 hours following the last dose administration on Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) following multiple ascending doses</measure>
    <time_frame>Up to 96 hours following the last dose administration on Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)] following multiple ascending doses</measure>
    <time_frame>Up to 96 hours following the last dose administration on Day 4</time_frame>
    <description>t(1/2) on the last day of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve during a dosing interval (AUCtau)</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>AUCtau is the area under the plasma concentration-time curve during a dosing interval</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AC-082, Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Single Ascending Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive a single dose of the matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-082, Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive the matched placebo for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-082</intervention_name>
    <description>Hard gelatin capsules for oral administration</description>
    <arm_group_label>AC-082, Single Ascending Dose</arm_group_label>
    <arm_group_label>AC-082, Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo capsules for oral administration</description>
    <arm_group_label>Placebo, Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Placebo, Single Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  Signed informed consent

          -  Healthy on the basis of physical examination,12-lead electrocardiogram and laboratory
             tests

          -  Males and females of non-childbearing potential, aged between 18 and 60 years (all
             inclusive)

          -  Women must have a negative serum pregnancy test at Screening and a negative urine
             pregnancy test predose on Day -1

          -  Body mass index (BMI) between 18.0 and 29.9 kg/m2 (inclusive)

          -  Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR)
             between 90-140 mmHg, 50-90 mmHg and 50-90 bpm (all inclusive), respectively

        Key exclusion Criteria:

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition which might interfere with the absorption, distribution, metabolism
             or excretion of the study treatment

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions

          -  Any circumstances or conditions, which, in the opinion of the Investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Litherland, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <keyword>first-in-man</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

